Prognoza
Średnia cena docelowa analityków wynosi 1,82 € (+127,50%). Mediana wynosi 1,82 € (+127,50%).
| Kupuj |
8 |
| Trzymaj |
6 |
| Sprzedaj |
1 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Cardiff Oncology outlines phase III plan for Onvansertib, financing open
Cardiff Oncology confirmed exclusive worldwide rights to Onvansertib after an agreement with Nerviano and presented convincing phase II data at an investor conference, reporting an overall response rate of 72% for the Onvansertib plus FOLFIRI/Bevacizumab combination. The FDA agreed to a simplified 1:1 randomized phase III design (CRDF‑004) with about 640 patients, with overall response rate as the primary endpoint potentially enabling accelerated approval. The company is targeting a global launch in early 2026 but still needs to secure $128–176 million to fund the trial and is weighing capital‑markets options, non‑dilutive financings and partnerships. » Więcej na de.investing.com
Cardiff Oncology secures $10 million in registered direct offering
Cardiff Oncology completed the sale of 8,571,429 shares of common stock and accompanying warrants at $1.05 each in a registered direct offering, yielding gross proceeds of approximately $10 million before fees. Officers and directors purchased 731,707 shares and warrants at $1.435 each; the warrants have an exercise price of $1.31, are exercisable no earlier than six months after issuance or after approval of the equity increase, and expire five and a half years after they first become exercisable. H.C. Wainwright & Co. acted as exclusive placement agent. Cardiff Oncology intends to use the net proceeds for working capital and general corporate purposes. » Więcej na de.investing.com
Cardiff Oncology presents preclinical Onvansertib data at AACR meeting
Cardiff Oncology will present preclinical data on its PLK1 inhibitor Onvansertib at the AACR 2026 annual meeting, which are intended to show that Onvansertib enhances the antitumor activity of trastuzumab‑deruxtecan (T‑DXd) and overcomes resistance in treatment‑refractory HER2‑low breast cancer models. Onvansertib is an orally administered PLK1 inhibitor currently being tested in a phase 2 trial in RAS‑mutant metastatic colorectal cancer and is being investigated in additional trials across various tumor types. The poster (abstract no. 329) will be made available on the company’s website after the presentation. » Więcej na de.investing.com
Cardiff Oncology presents strong phase‑2 data for onvansertib in RAS‑mutant colorectal cancer
Onvansertib, combined with FOLFIRI and bevacizumab, showed an overall response rate of 72.2%, well above the 42% benchmark. Cardiff plans a global phase‑3 trial at 30 mg in the first half of 2026, subject to discussions with the FDA. The company has $58.3 million in cash, which is expected to fund operations until early 2027 but does not cover the anticipated costs of the phase‑3 trial. Pfizer invested $15 million and is serving as a CRO partner; Cardiff retains full rights to the program, is exploring additional indications, and anticipates regulatory and financial challenges. » Więcej na de.investing.com
Cardiff Oncology stock plunges after phase 2 update on Onvansertib
Cardiff Oncology reported that Onvansertib combined with FOLFIRI/Bevacizumab showed dose-dependent higher overall response rates; the 30 mg group achieved a confirmed ORR of 72.2% versus 43.2% with standard therapy, and progression-free survival has not yet been reached. Despite the positive assessment and the announcement to advance the 30 mg dose into a registrational trial, shares fell about 30% in premarket trading — investors appeared disappointed, apparently due to expectations of stronger signals or concerns about statistical significance. Onvansertib was well tolerated; the most common adverse event was neutropenia. The company appointed an interim CEO and announced personnel changes in finance, and said it will present final data and a plan for the registrational study in H1 2026 in coordination with the FDA. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale Cardiff Oncology osiągnęła przychody w wysokości 150,97 tys. € i zysk netto w wysokości -7,82 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 150,97 tys. | 47,64% |
| Zysk brutto | -8,14 mln | 8059,46% |
| Zysk netto | -7,82 mln | 18,49% |
| EBITDA | -7,74 mln | 15,60% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 59,38 mln € |
Liczba akcji | 77,8 mln |
Maksimum/minimum z 52 tygodni | 3,01 € - 0,65 € |
| Dywidendy | Nie |
Beta | 1,56 |
C/Z (PE Ratio) | -1,53 |
PEG (PEG Ratio) | -0,03 |
C/WK (PB Ratio) | 2,27 |
C/S (PS Ratio) | 116,76 |
Profil spółki
Cardiff Oncology, Inc., spółka onkologiczna będąca na etapie badań klinicznych, opracowuje terapie dla pacjentów z nowotworami w Kalifornii. Jej wiodącym kandydatem na lek jest onvansertib, doustny selektywny inhibitor kinazy Polo-like 1 (PLK1) przeznaczony do terapii przeciwnowotworowych; CY140, inhibitor PLK1, PLK2 i PLK3, który znajduje się w badaniach fazy 1/2 dotyczących guzów litych i białaczek; przerzutowy rak jelita grubego, który jest przedmiotem badań klinicznych; oraz TROV-054, będący w fazie 1b/2 badaniem dotyczącym schematu FOLFIRI i bewacyzumabu. Spółka TROV-053 jest również w fazie II badania klinicznego w połączeniu z Zytigą w leczeniu przerzutowego, opornego na kastrację raka gruczołu krokowego. Spółka świadczy usługi głównie dla producentów farmaceutycznych. Wcześniej spółka była znana jako Trovagene, Inc., a w maju 2012 roku zmieniła nazwę na Cardiff Oncology, Inc. Cardiff Oncology, Inc. została założona w 1999 roku i ma siedzibę w San Diego w Kalifornii.
| Nazwa | Cardiff Oncology |
| CEO | Mani Mohindru |
| Siedziba | San Diego,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Dobra podstawowe |
| Branża | Żywność |
| Debiut giełdowy | 27.07.2004 |
| Pracownicy | 31 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | CRDF |
Frankfurt | XE7C.F |
Düsseldorf | XE7C.DU |
München | XE7C.MU |